NTC's Acquisition of Pharmathen's Ophthalmology Division Signifies Strategic Growth in the Market

NTC Expands Its Portfolio through Pharmathen Acquisition

In a significant move that is set to bolster its standing in the ophthalmology sector, NTC S.r.l., a leading Italian pharmaceutical company focusing on eye care, has completed the acquisition of Pharmathen's ophthalmology business with support from its main shareholder, Wise Equity. This transaction marks a vital milestone in NTC’s strategic plan, allowing the company to enhance its glaucoma treatment offerings and meet the growing demand in the industry.

Transaction Overview

The acquisition has positioned NTC to achieve an annual revenue of approximately €100 million, with more than 80% of this coming from ophthalmology related products. This development will not only strengthen NTC's market position in Europe but also facilitate its entry into the robust U.S. market, thus widening its global footprint.

With this deal finalized on December 10, 2025, NTC has taken on a consolidated portfolio of glaucoma treatments produced across various European and U.S.-based third-party facilities. These products, delivered through an established B2B network, are crucial for NTC as it looks to expand its therapeutic offerings.

Strategic Intent

Riccardo Carbucicchio, the CEO of NTC, emphasized the strategic nature of this acquisition, stating, “The purchase of Pharmathen's ophthalmology division is a significant addition to our portfolio. By integrating these advanced therapies into our offerings, we reinforce our commitment to providing patients with safe and reliable long-term treatments.” NTC's dedication to patient care is further exemplified by its emphasis on high-quality, preservative-free formulations that have already been recognized for their safety and efficacy in clinical settings.

By leveraging its existing global partner network, NTC is poised to not only present its current portfolio to new partners but also to internationalize the integrated offerings from Pharmathen.

Growth and Market Dynamics

John Nason, the Group CEO of Pharmathen, noted that transitioning their ophthalmic products to a partner specialized in ophthalmology like NTC ensures continuous investments and reliable supply channels, thereby adding sustainable value for clients.

Additionally, as the global demand for glaucoma treatments escalates, NTC will play a critical role in addressing the needs of patients worldwide. Currently, there are around 80 million individuals living with glaucoma, a number that is projected to rise to almost 112 million by 2040 if treatments and solutions are not prioritized properly.

The acquisition opens up vast commercial synergies aimed at expanding therapeutic coverage and capturing new market opportunities on an international scale. Especially in Italy and Spain, where NTC has established direct sales teams targeting ophthalmologists, there will be significant potential to broaden their product offerings to include glaucoma treatments effectively.

Meeting Clinical Needs

Over the last decade, NTC has built a competitive pipeline addressing critical clinical needs ranging from antibiotic therapies to solutions for allergies and dry eyes. The recent acquisition reinforces NTC’s role as a major player in European ophthalmology, as it strengthens their commercial reach across more than 100 countries and over 250 partners.

Ascanio Recchi, Investment Manager at Wise Equity, highlighted that “NTC’s expansion into glaucoma significantly amplifies its commercial platform while enhancing the ability to create long-term value amidst a sector witnessing rising demands.”

Conclusion

NTC’s strategic acquisition of Pharmathen exemplifies its commitment to patient-centered care by enhancing its glaucoma portfolio and allowing for greater international expansion. With a well-established presence in the ophthalmology market and an enhanced suite of products, NTC is set to make substantial strides in addressing global healthcare needs in the ophthalmic sector.

For further information on NTC, Pharmathen, and Wise Equity, please visit their respective websites. This acquisition reflects the ongoing transformation and growth within the pharmaceutical industry, particularly in the niche market of ophthalmology, ensuring that companies remain competitive and responsive to patient needs.